BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  Applicant  Scotia  Pharmaceuticals  Limited  submitted  on  5  October  1999  an  application  for 
Marketing Authorization to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for FOSCAN, in accordance with the centralised procedure falling within the scope of Part B of the 
Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. W.F. van der Giesen 
Co-Rapporteur:  Dr. J. Ersbøll 
During the appeal procedure the Rapporteur and Co-Rapporteur were as follows: 
Rapporteur:   
Dr. T. Salmonsson 
Co-Rapporteur:  Dr. D. Lyons 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. In the USA, 
Foscan was designated an orphan drug status in October 1999. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 22 October 1999. 
The Rapporteur's initial Assessment Report was circulated to all CPMP members on 3 January 
2000. The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 10 
January 2000. 
During  the  meeting  on  15-17  February  2000,  the  CPMP  agreed  on  the  Consolidated  List  of 
Questions to be sent to the Applicant. The final Consolidated List of Questions was sent to the 
Applicant on 17 February 2000. 
The  summary  report  of  the  inspection  carried  out  between  24  and  27  March  2000  of  the 
manufacturing sites Nycomed Amersham, Gloucester, UK and Scotia Pharmaceuticals Limited, 
Carlisle, UK was issued on 31 March 2000. 
The  Applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  
17 August 2000. 
The Rapporteur circulated the Joint Response Assessment Report on the Applicant’s responses 
to the List of Questions to all CPMP members on 19 September 2000. 
During the meeting on 17-19 October 2000 the CPMP agreed on the List of Outstanding Issues 
to be sent to  the  Applicant. The final List of Outstanding Issues  was sent to the  Applicant on  
17 October 2000. 
The  Applicant  submitted  written  responses  to  the  consolidated  List  of  Outstanding  Issues  on  
30 October 2000. 
The Rapporteur circulated the Joint Response Assessment Report on the company’s responses 
to the List of Outstanding Issues to all CPMP members on 7 November 2000. 
During the CPMP meeting on 12-14 December 2000 outstanding issues were addressed by the 
Applicant  during  a  an  oral  explanation  before  the  CPMP.  A  List  of  Outstanding  Issues  to  be 
addressed at an expert meeting was adopted. 
On  22  January  2001,  an  Expert  Group  meeting  took  place  addressing  the  List  of  Outstanding 
Issues. 
1/2 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
• 
During the meeting on 23-25 January 2001, the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  negative  opinion  for  granting  a 
Marketing Authorisation to Foscan. 
On 14 February 2001 the  Applicant  provided the formal  notice of appeal against the negative 
Opinion of the CPMP dated 25 January 2001. 
On the 5 April 2001 the Applicant submitted grounds for appeal. 
The Rapporteur circulated the Joint Assessment Report on the grounds for appeal submitted by 
the Applicant 4 June 2001. 
On 25 June 2001 an ad hoc Expert Meeting took place addressing the grounds for refusal raised 
in the negative opinion. 
During its meeting on 26-27 June 2001, the CPMP in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation under exceptional circumstances to Foscan. 
Data on the CPMP Assessment Report providing additional clarifications were accepted by the 
CPMP on 13 July 2001. 
2/2 
EMEA 2005 
 
 
 
 
 
 
